Syncona Creates Second Gene Therapy Company With £25m Financing
This article was originally published in Scrip
The Wellcome Trust's investment subsidiary Syncona LLP has put £25m of series A financing into a new gene therapy company, Freeline Therapeutics, spun off from University College London (UCL) via its technology transfer arm UCL Business PLC. Freeline's initial focus will be on bleeding disorders.
Register for our free email digests: